Veradigm (STU:AL21) Research & Development: €103.4 Mil (TTM As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AL21 Veradigm Inc STU:AL21
17 GF Score
Price €3.40
View Full Analysis

What is Veradigm Research & Development?

Veradigm STU:AL21 17 Research & Development is €103.4 Mil as of Dec. 2022. GuruFocus rates STU:AL21 with a GF Score™ of 17/100.

Research & Development is the aggregate amount of research and development expenses during the year. Veradigm's Research & Development for the six months ended in Dec. 2022 was €92.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2022 was €103.4 Mil.

Veradigm  (STU:AL21) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Veradigm Research & Development Related Terms

Veradigm Research & Development Historical Data

* Premium members only.

The historical data trend for Veradigm's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veradigm Research & Development Chart

Veradigm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 220.90 64.61 74.43 92.41 103.43

Veradigm Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 May09 May10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 220.90 64.61 74.43 92.41 103.43
STU:AL21
17GF Score
Veradigm Inc STU:AL21
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veradigm Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Dec. 2022 was €103.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €103.4 Mil mean?
Veradigm (STU:AL21) has a Research & Development of €103.4 Mil as of Dec. 2022. Research and development expense is the total cost for research and development activities. View historical data on Veradigm and its competitors.
Is Veradigm's Research & Development too high?
Veradigm's current Research & Development is €103.4 Mil. Overall, Veradigm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's Research & Development compare to CTEV and EVH?
Veradigm's Research & Development of €103.4 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Veradigm and its competitors. Veradigm's current Research & Development is €103.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current Research & Development of €103.4 Mil. The current Research & Development is €103.4 Mil. Veradigm's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Veradigm (STU:AL21), the current Research & Development is €103.4 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veradigm Business Description

Other Exchanges MDRX:USA
Address 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL, USA, 60654
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
17GF Score

Get the complete analysis for STU:AL21

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price